Villani Alessia, Fabbrocini Gabriella, Costa Claudia, Scalvenzi Massimiliano
Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Dermatol Ther (Heidelb). 2020 Jun;10(3):401-412. doi: 10.1007/s13555-020-00378-8. Epub 2020 Apr 15.
Hedgehog inhibitors are promising alternative treatments for patients with advanced basal cell carcinomas. Sonidegib (Odomzo), an oral smoothened (SMO) antagonist, is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who present recurrence following surgery or radiation therapy, or those who are not candidates for surgery or radiotherapy. Several studies and randomized controlled trials have been conducted to evaluate the efficacy, safety, and tolerability of this new molecule that has demonstrated a good response rate (44%). Grade 1-2 adverse events have also been reported. Further studies of real-world experiences are needed to better understand the correct management of the drug, alternative dosing regimens, and differences with other hedgehog inhibitors. This article provides a complete overview of the pharmacology and pharmacokinetics of sonidegib and a report of the trials and studies conducted. The most frequent adverse events and their correct management are also discussed.
刺猬信号通路抑制剂是晚期基底细胞癌患者很有前景的替代治疗方法。索尼德吉（Odomzo），一种口服的 smoothened（SMO）拮抗剂，适用于治疗成年局部晚期基底细胞癌（laBCC）患者，这些患者在手术或放疗后出现复发，或那些不适合手术或放疗的患者。已经进行了多项研究和随机对照试验来评估这种新分子的疗效、安全性和耐受性，其显示出良好的缓解率（44%）。也有1-2级不良事件的报告。需要进一步开展真实世界经验的研究，以更好地了解该药物的正确管理、替代给药方案以及与其他刺猬信号通路抑制剂的差异。本文全面概述了索尼德吉的药理学和药代动力学，并报告了所进行的试验和研究。还讨论了最常见的不良事件及其正确管理。
